In adults with type 2 diabetes in a cross-sectional study, liraglutide use was linked to gastrointestinal issues.
In plain wordsIn adults with diabetes, liraglutide use was linked to gastrointestinal issues.
- Peptide
- Liraglutide
- Outcome
- Direction not reportedGastrointestinal issues
- Study
n: not reported in source
- Outcome group
- Gastrointestinal adverse events · Gastrointestinal
- Studied dose
- Dose not stated
Source sentences
Metformin, liraglutide, and empagliflozin were linked to gastrointestinal issues.
6 context sentences(design, population, supporting numbers)
A multicenter, cross-sectional observational study was conducted across diabetes outpatient clinics in Egypt from February 2024 to May 2024.
Adult patients with type 2 diabetes on antidiabetic regimens were enrolled.
Data was collected through medical records and patient interviews, including demographics, clinical history, laboratory results, diabetes complications, and treatment-related adverse events.
Univariate logistic regression analyses were performed to assess the associations between antidiabetic medications and diabetes-related complications and adverse outcomes.
Unadjusted odds ratios (ORs) with 95% confidence intervals were reported.
Statistical significance was set at p-value ≤ 0.05.